IDEAYA ( IDYA ) Q2 Net Loss Improves 27%
IDEAYA Biosciences ( NASDAQ:IDYA ) , a precision oncology company focused on developing targeted therapies for cancer, reported its second-quarter earnings on August 5, 2025. The company did not report any revenue for the quarter.
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SOUTH SAN FRANCISCO, Calif., Aug. 1, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc.
This Royal Caribbean Cruises Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - IDEAYA Biosciences ( NASDAQ:IDYA ) , Carnival ( NYSE:CCL )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. TD Cowen analyst Kevin Kopelman initiated coverage on Royal Caribbean Cruises Ltd.
This NRG Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Eupraxia Pharmaceuticals ( NASDAQ:EPRX ) , IDEAYA Biosciences ( NASDAQ:IDYA )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. HC Wainwright & Co. analyst Brandon Folkes initiated coverage on Eupraxia Pharmaceuticals Inc.
ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders - Keros Therapeutics ( NASDAQ:KROS )
Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna Seth
Down -8.63% in 4 Weeks, Here's Why You Should You Buy the Dip in IDEAYA Biosciences ( IDYA )
The heavy selling pressure might have exhausted for IDEAYA Biosciences (IDYA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend ...
IDEAYA Biosciences, Inc. ( IDYA ) Reports Q4 Loss
IDEAYA Biosciences (IDYA) delivered earnings and revenue surprises of -122.39% and 0%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Sage Therapeutics, Inc. ( SAGE ) Reports Q4 Loss, Lags Revenue Estimates
Sage Therapeutics (SAGE) delivered earnings and revenue surprises of -7.59% and 11.20%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About IDEAYA Biosciences ( IDYA ) Rating Upgrade to Buy
IDEAYA Biosciences (IDYA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Jim Cramer Says This Tobacco Stock Is 'Undervalued' But He's Not Recommending It - AstraZeneca ( NASDAQ:AZN )
On CNBC's "Mad Money Lightning Round," Jim Cramer said Altria Group, Inc. MO is "undervalued," but he is not going to recommend tobacco stocks. On Oct. 31, the company reported third-quarter adjusted earnings per share of $1.38. It beat the street view of $1.35.
Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences ( IDYA ) : Here's What You Should Know
The consensus price target hints at an 81.9% upside potential for IDEAYA Biosciences (IDYA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Cognex ( NASDAQ:CGNX )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Deutsche Bank analyst Bryan Keane downgraded the rating for Marqeta, Inc.
Earnings Preview: Gilead Sciences ( GILD ) Q3 Earnings Expected to Decline
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: IDEAYA Biosciences, Inc. ( IDYA ) Q3 Earnings Expected to Decline
IDEAYA Biosciences (IDYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IDEAYA Trades Down As Eye Cancer Treatment Shows Promise - IDEAYA Biosciences ( NASDAQ:IDYA ) , Pfizer ( NYSE:PFE )
Ideaya Biosciences Inc. IDYA, a precision medicine oncology company, released interim Phase 2 clinical trial data. The data centers on darovasertib in neoadjuvant ( therapy before surgery ) for uveal melanoma ( UM ) and an FDA Type C meeting on registrational trial design for regulatory approval ...
Oracle To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Tuesday - Oracle ( NYSE:ORCL )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. TD Cowen raised the price target for Oracle Corporation ORCL from $165 to $180.
IDEAYA Biosciences, Inc. ( IDYA ) Expected to Beat Earnings Estimates: Should You Buy?
IDEAYA Biosciences (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How Much Upside is Left in IDEAYA Biosciences ( IDYA ) ? Wall Street Analysts Think 32.97%
The mean of analysts' price targets for IDEAYA Biosciences (IDYA) points to a 33% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Stocks To Watch: IDEAYA Biosciences Sees RS Rating Rise To 86
IDEAYA Biosciences ( IDYA ) had its Relative Strength ( RS ) Rating upgraded from 80 to 86 Friday.
Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure
IDEAYA Biosciences (IDYA) and uniQure N.V. (QURE) are in the spotlight following positive pipeline updates.
Kura Sushi Posts Weak Q3 Results, Joins LegalZoom.com And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Kura Sushi USA ( NASDAQ:KRUS )
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Wednesday. Shares of Kura Sushi USA, Inc. KRUS fell sharply in today's pre-market trading after the company posted downbeat results for its third quarter on Tuesday.
IDEAYA ( IDYA ) Up on Upbeat Phase II Bladder & Lung Cancer Data
IDEAYA (IDYA) gains 15% on positive clinical data from its phase II study evaluating the 30 mg monotherapy expansion dose of IDE397 to treat MTAP-deletion urothelial and NSCLC patients.
Company News for July 9, 2024
Companies In The Article Are:MORF, LLY, IDYA, ETSY, INTC.
Strength Seen in IDEAYA Biosciences ( IDYA ) : Can Its 15.3% Jump Turn into More Strength?
IDEAYA Biosciences (IDYA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
IDEAYA Biosciences Highlights 'Encouraging' Preliminary Efficacy, Safety Profile For Patients With Hard-To-Treat Cancer - IDEAYA Biosciences ( NASDAQ:IDYA )
Monday, IDEAYA Biosciences Inc IDYA released clinical data for the IDE397 Phase 2 monotherapy expansion dose in methylthioadenosine phosphorylase-deletion urothelial and non-small cell lung cancer patients ( NSCLC ) .
Corning Increases Sales Forecast, Joins Morphic Holding, Lucid Group And Other Big Stocks Moving Higher On Monday - Corning ( NYSE:GLW )
U.S. stocks were higher, with the Dow Jones index surging around 200 points on Monday. Shares of Corning Incorporated GLW rose sharply during Monday's session after the company increased its second-quarter core sales guidance.
IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer
IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class ... PR ...
IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024
IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion ... PR ...
IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors
IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A ... PR ...
Stocks Showing Improved Relative Strength: IDEAYA Biosciences
On Monday, IDEAYA Biosciences ( IDYA ) got a positive adjustment to its Relative Strength ( RS ) Rating, from 70 to 79. ↑ X What Are The Magnificent Seven Stocks? NOW PLAYING What Are The Magnificent Seven Stocks?
Stocks Flashing Renewed Technical Strength: IDEAYA Biosciences
IDEAYA Biosciences ( IDYA ) saw a positive improvement to its Relative Strength ( RS ) Rating on Tuesday, rising from 69 to 81. X IBD's proprietary rating measures market leadership with a 1 ( worst ) to 99 ( best ) score.
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SOUTH SAN FRANCISCO, May 31, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. ( NASDAQ: IDYA ) , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on May 30, 2024, the Compensation Committee of IDEAYA's Board of ...
IDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations Events
SOUTH SAN FRANCISCO, Calif., May 29, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. ( NASDAQ: IDYA ) , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events.
IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business Development
IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business ... PR ...
IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
• ASCO 2024 oral presentation of darovasertib neoadjuvant UM Phase 2 investigator-sponsored trial on , and targeting neoadjuvant UM update in over 30 patients from Phase 2 company-sponsored trial and regulatory guidance both in H2 2024 • Selected move-forward Phase 2 dose for IDE397 in MTAP ...
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SOUTH SAN FRANCISCO, Calif., April 26, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. ( NASDAQ: IDYA ) , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on April 25, 2024, the Compensation Committee of IDEAYA's Board ...
IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event
SOUTH SAN FRANCISCO, Calif., April 1, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. ( NASDAQ: IDYA ) , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in an upcoming investor relations event.
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
• Targeting two independent Phase 2 clinical efficacy updates for darovasertib in neoadjuvant uveal melanoma ( UM ) in mid-2024, including from the Phase 2 IST and Phase 2 company-sponsored study • Targeting FDA regulatory guidance on darovasertib in neoadjuvant UM indication in 2024 • Ongoing ...
IDEAYA Biosciences, Inc. ( IDYA ) Moves 7.6% Higher: Will This Strength Last?
IDEAYA Biosciences, Inc. (IDYA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SOUTH SAN FRANCISCO, Calif., Dec. 29, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. ( NASDAQ: IDYA ) , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on December 28, 2023, the Compensation Committee of IDEAYA's ...
IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy® and IDE397 Combination in MTAP-Deletion Bladder Cancer
IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy® and IDE397 Combination ... PR ...
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 4, 2023
SOUTH SAN FRANCISCO, Calif., Dec. 3, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. ( NASDAQ: IDYA ) , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced agenda topics for its Investor R&D Day.
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 4, 2023 - IDEAYA Biosciences ( NASDAQ:IDYA )
SOUTH SAN FRANCISCO, Calif., Dec. 3, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. IDYA, a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced agenda topics for its Investor R&D Day.
Can IDEAYA Biosciences, Inc. ( IDYA ) Climb 25.48% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for IDEAYA Biosciences, Inc. (IDYA) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
IDEAYA Biosciences, Inc. ( IDYA ) Reports Q3 Loss, Lags Revenue Estimates
IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 2.13% and 22.98%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
IDEAYA Biosciences, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Nov. 7, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. ( Nasdaq: IDYA ) , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the third quarter ended ...
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
Updated data from azenosertib monotherapy study with longer follow up shows 37% ORR and mPFS of 6.5 months in heavily pretreated ovarian and uterine serous carcinoma patients ...
Biotechs Bounce. New Highs For Ideaya, Olema And Vertex.
Biotechs rallied this week, a strong indication that "risk on" is back on after Fed Chair Jerome Powell said interest rates won't be raised again right now. This sector is the non-value stock sector - investors going for growth like to place money here when they feel that a bottom may be in place.
AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS
Amgen ( NASDAQ:AMGN ) today announced financial results for the third quarter of 2023 1 . References in this release to "non-GAAP" measures, measures presented "on a non-GAAP basis" and "free cash flow" ( computed by subtracting capital expenditures from operating cash flow ) refer to ...
Why Ideaya Biosciences Stock Is Plummeting Today
Ideaya stock is getting hit hard following a recent press release from the company.
